Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL018
MIFTS: 49

Childhood Medulloblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Medulloblastoma

About this section

MalaCards integrated aliases for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma 11 19 14
Medulloblastoma, Childhood 19 71
Pediatric Medulloblastoma 11
Medulloblastoma Childhood 53

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:3869
MeSH 43 D008527
NCIt 49 C3997
UMLS 71 C0278510
Sources

Summaries for Childhood Medulloblastoma

About this section

GARD: 19 A medulloblastoma occurring in children.

MalaCards based summary: Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to ewing sarcoma and pilocytic astrocytoma, and has symptoms including vomiting, headache and gait ataxia. An important gene associated with Childhood Medulloblastoma is CRNDE (Colorectal Neoplasia Differentially Expressed), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Povidone K30 and Metformin have been mentioned in the context of this disorder. Affiliated tissues include brain, nk cells and spinal cord, and related phenotypes are Increased cell viability after pRB stimulation and Increased cell death in HCT116 cells
Sources

Related Diseases for Childhood Medulloblastoma

About this section

Diseases related to Childhood Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 30.6 TP53 MYCN MYC KDM4C H2AC18
2 pilocytic astrocytoma 30.3 TP53 TERT MGMT EGFR
3 supratentorial primitive neuroectodermal tumor 30.3 TP53 SHH MYCN MYC
4 central nervous system cancer 30.2 TP53 MGMT KDM4C H2AC18 EGFR
5 medulloblastoma 30.1 TP53 TERT SUFU SHH PTCH1 MYCN
6 blastoma 30.0 TP53 SHH MYCN EGFR
7 connective tissue benign neoplasm 29.9 TP53 PTCH1 H2AC18
8 leukemia, acute lymphoblastic 29.8 TP53 MYCN MYC KDM4C H2AC18
9 rhabdoid cancer 29.8 TP53 SHH KDM4C H2AC18
10 inherited cancer-predisposing syndrome 29.8 TP53 TERT SUFU PTCH1 EGFR
11 bap1 tumor predisposition syndrome 29.8 TP53 TERT SUFU PTCH1 EGFR
12 neuroblastoma 29.8 TP53 TERT SHH MYCN MYC ERBB2
13 brain cancer 29.8 TP53 TERT SHH PTCH1 MYCN MGMT
14 cerebellar medulloblastoma 29.8 TP53 SUFU SHH PTCH1 MYCN GLI1
15 greig cephalopolysyndactyly syndrome 29.7 SUFU SHH PTCH1 GLI2 GLI1
16 large cell medulloblastoma 29.7 SUFU SHH PTCH1 MYCN MYC GLI2
17 adult medulloblastoma 29.6 SUFU SHH PTCH1 MYCN KDM4C GLI2
18 desmoplastic nodular medulloblastoma 29.6 TP53 SUFU SHH PTCH1 MYCN MYC
19 basal cell carcinoma 29.6 TP53 SUFU SHH PTCH1 H2AC18 GLI2
20 high grade glioma 29.5 TP53 TERT MGMT KDM4C H2AC18 EGFR
21 basal cell nevus syndrome 29.4 TP53 TERT SUFU SHH PTCH1 MYCN
22 wilms tumor 1 29.4 TP53 TERT MYCN MYC KDM4C H2AC18
23 glioblastoma 29.1 TP53 TERT SHH MYCN MYC MGMT
24 leukemia, acute myeloid 29.1 TP53 TERT MYCN MYC KDM4C H2AC18
25 rhabdomyosarcoma 28.9 TP53 TERT SUFU SHH PTCH1 MYCN
26 atypical teratoid rhabdoid tumor 28.9 TP53 SUFU SHH PTCH1 MYCN MYC
27 li-fraumeni syndrome 28.9 TP53 TERT SUFU SHH PTCH1 MYCN
28 meningioma, familial 28.6 TP53 TERT SUFU SHH PTCH1 MYC
29 gastric cancer 28.3 TP53 TERT SHH PTCH1 MYC MGMT
30 hypoganglionosis 10.4 ERBB3 ERBB2
31 adult spinal cord glioblastoma multiforme 10.4 TERT MGMT
32 acneiform dermatitis 10.4 ERBB4 ERBB3 EGFR
33 diffuse glioma, h3 g34 mutant 10.4 TERT MGMT
34 squamous blepharitis 10.4 ERBB4 ERBB3 EGFR
35 spinal ependymoma, mycn-amplified 10.4 MYCN MYC
36 islet cell tumor 10.4
37 mucinous lung adenocarcinoma 10.4 NRG1 ERBB3 EGFR
38 cerebral primitive neuroectodermal tumor 10.4 MYCN MYC
39 mixed cell adenoma 10.4 NRG1 ERBB4 EGFR
40 primary ovarian insufficiency 6 10.3 SUFU SHH
41 holoprosencephaly, recurrent infections, and monocytosis 10.3 PTCH1 GLI2
42 medullomyoblastoma 10.3 SUFU SHH MYC
43 carcinosarcoma 10.3 TP53 ERBB2 EGFR
44 apocrine adenosis of breast 10.3 TP53 ERBB2
45 gestational ovarian choriocarcinoma 10.3 TP53 MYC ERBB2
46 esophagus verrucous carcinoma 10.3 TP53 EGFR
47 polydactyly, preaxial ii 10.3 SHH PTCH1
48 gallbladder signet ring cell adenocarcinoma 10.3 MYC ERBB3
49 melanotic medulloblastoma 10.3 SUFU SHH
50 breast sarcoma 10.3 TP53 MYC ERBB2

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:



Diseases related to Childhood Medulloblastoma
Sources

Symptoms & Phenotypes for Childhood Medulloblastoma

About this section

UMLS symptoms related to Childhood Medulloblastoma:


vomiting; headache; gait ataxia

GenomeRNAi Phenotypes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell viability after pRB stimulation GR00230-A-1 8.92 EGFR ERBB2 ERBB3 ERBB4
2 Increased cell death in HCT116 cells GR00103-A-0 8.65 CUL4A

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.45 EGFR ERBB2 ERBB3 ERBB4 GLI1 GLI2
2 neoplasm MP:0002006 10.41 CUL4A EGFR ERBB2 ERBB3 GLI1 KDM4C
3 homeostasis/metabolism MP:0005376 10.41 CUL4A EGFR ERBB2 ERBB3 GLI2 KDM4C
4 normal MP:0002873 10.4 EGFR ERBB2 ERBB3 ERBB4 GLI1 GLI2
5 growth/size/body region MP:0005378 10.4 CUL4A EGFR ERBB2 ERBB3 GLI1 GLI2
6 endocrine/exocrine gland MP:0005379 10.39 CUL4A EGFR ERBB2 ERBB3 ERBB4 GLI1
7 no phenotypic analysis MP:0003012 10.32 EGFR GLI1 GLI2 KDM4C MGMT MYC
8 muscle MP:0005369 10.31 EGFR ERBB2 ERBB3 ERBB4 GLI2 MYC
9 embryo MP:0005380 10.31 EGFR ERBB2 ERBB3 ERBB4 GLI1 GLI2
10 cellular MP:0005384 10.31 CUL4A EGFR ERBB2 ERBB3 ERBB4 GLI1
11 digestive/alimentary MP:0005381 10.29 CUL4A EGFR ERBB2 ERBB3 GLI1 GLI2
12 limbs/digits/tail MP:0005371 10.25 EGFR ERBB2 GLI1 GLI2 MYC MYCN
13 craniofacial MP:0005382 10.2 EGFR ERBB2 ERBB4 GLI1 GLI2 MYC
14 behavior/neurological MP:0005386 10.18 CUL4A ERBB2 ERBB3 ERBB4 GLI1 GLI2
15 respiratory system MP:0005388 10.17 EGFR ERBB2 ERBB3 ERBB4 GLI1 GLI2
16 liver/biliary system MP:0005370 10.16 CUL4A EGFR MYC MYCN SHH SUFU
17 cardiovascular system MP:0005385 10.14 EGFR ERBB2 ERBB3 ERBB4 MYC MYCN
18 pigmentation MP:0001186 10.08 EGFR ERBB3 MYC PTCH1 SUFU TP53
19 reproductive system MP:0005389 10.07 CUL4A EGFR ERBB2 ERBB4 GLI1 GLI2
20 skeleton MP:0005390 9.9 EGFR ERBB2 GLI1 GLI2 MYC MYCN
21 mortality/aging MP:0010768 9.89 CUL4A EGFR ERBB2 ERBB3 ERBB4 GLI1
22 integument MP:0010771 9.4 EGFR ERBB2 ERBB3 ERBB4 GLI2 KDM4C
Sources

Drugs & Therapeutics for Childhood Medulloblastoma

About this section

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone K30 Approved, Experimental, Withdrawn Phase 3 9003-39-8 6917 131751496
2
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
3
Titanium dioxide Approved Phase 3 13463-67-7
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
9
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
10
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
11
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
12
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
15 Hypoglycemic Agents Phase 3
16 Alkylating Agents Phase 3
17 Antineoplastic Agents, Alkylating Phase 3
18 Immunosuppressive Agents Phase 3
19 Folic Acid Antagonists Phase 3
20 Folate Phase 3
21 Antirheumatic Agents Phase 3
22 Vitamin B9 Phase 3
23
Etoposide phosphate Phase 3 16760419
24 Antimitotic Agents Phase 3
25 Vitamin B Complex Phase 3
26 Antimetabolites Phase 3
27 Tubulin Modulators Phase 3
28 Dermatologic Agents Phase 3
29 Vitamins Phase 3
30 Trace Elements Phase 3
31 Antidotes Phase 3
32 Calcium, Dietary Phase 3
33 Micronutrients Phase 3
34 Adjuvants, Immunologic Phase 3
35 Immunologic Factors Phase 3
36
Calcium Nutraceutical Phase 3 7440-70-2 271
37
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
38
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605 16129706
39
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
40
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
41
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908
42
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
43
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
44
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
45
Camptothecin Experimental Phase 2 7689-03-4 24360
46
Tipifarnib Investigational Phase 2 192185-72-1 159324
47
Genistein Investigational Phase 2 446-72-0 5280961
48 Radiopharmaceuticals Phase 2
49
Edotreotide Phase 2 23724894
50 Indium-111-octreotide Phase 2

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children's Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
2 Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Medulloblastoma Patients Recruiting NCT05230758 Phase 3 Metformin hydrochloride (HCl) 500mg tablet;Placebo
3 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial Active, not recruiting NCT00085735 Phase 3 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
4 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Active, not recruiting NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
5 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Terminated NCT01987596 Phase 3
6 Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors Completed NCT01869725 Phase 2 gallium Ga 68-edotreotide
7 Phase II Study of Bevacizumab Plus Irinotecan (Camptosarâ„¢) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
8 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
9 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
10 A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies Completed NCT00005811 Phase 2 topotecan hydrochloride
11 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
12 A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma Completed NCT01239316 Phase 2 Vismodegib
13 Phase IB Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AloCELYVIR (Mesenchymal Allogenic Cells + ICOVIR-5) in Children, Adolescent and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Relapse/Progression in Monotherapy Recruiting NCT04758533 Phase 1, Phase 2
14 PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma Recruiting NCT03904862 Phase 1, Phase 2 CX 4945
15 A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age Active, not recruiting NCT02017964 Phase 2 Carboplatin;Cyclophosphamide;Etoposide;Methotrexate;Vincristine Sulfate
16 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Suspended NCT03210714 Phase 2 Erdafitinib
17 A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors Terminated NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
18 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Terminated NCT02624388 Phase 2 Genistein;Placebo
19 A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma Terminated NCT04167618 Phase 1, Phase 2 177Lu-DTPA-omburtamab
20 Phase I Study of Intraventricular Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol Completed NCT02271711 Phase 1
21 A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 Completed NCT00822458 Phase 1 vismodegib
22 A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS Completed NCT00012181 Phase 1 alvocidib
23 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas Completed NCT00994500 Phase 1 vorinostat;bortezomib
24 A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors Completed NCT00077454 Phase 1 erlotinib hydrochloride;temozolomide
25 A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
26 Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
27 A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
28 Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors Completed NCT00063973 Phase 1 cilengitide
29 A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
30 A Phase 1 Study of SAHA (NSC# 701852) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors Completed NCT00217412 Phase 1 vorinostat;isotretinoin
31 A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS Completed NCT00363272 Phase 1 ispinesib
32 A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
33 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
34 A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS Completed NCT00053963 Phase 1 romidepsin
35 A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults With Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT) Recruiting NCT02962167 Phase 1
36 Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Recruiting NCT04185038 Phase 1
37 Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors Active, not recruiting NCT00638898 Phase 1 busulfan;melphalan;topotecan hydrochloride
38 Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors Active, not recruiting NCT02444546 Phase 1
39 Phase I Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric and Young Adult Patients Affected by Relapsed/Refractory Central Nervous System Tumors Not yet recruiting NCT05298995 Phase 1
40 Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors Terminated NCT02255461 Phase 1 palbociclib isethionate
41 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
42 A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma Withdrawn NCT01697514 Phase 1 LY2940680
43 Multi-center Retrospective Study on Clinical Features and Molecular Subgroups of Children and Adolescents With Medulloblastoma in China Unknown status NCT03288168
44 Child's Study of the Distant Impact of Posterior Fossa Injury on Motor Skills, Language, Cognitive Functioning, and Social Cognition - a Combination of Clinical Assessments and Brain Imaging Unknown status NCT04174820
45 Metabolomic Analysis of Body Fluid of Medulloblastoma in Children Based on New Mass Spectrometry and Its Application in Clinical Diagnosis and Recurrence Monitoring Unknown status NCT04065204
46 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens Completed NCT00919750
47 Efficacy Of Dual Task Training On Children With Ataxia After Medulloblastoma Resection Completed NCT04860934
48 Impact of Physical Activity on Postural Stability and Coordination in Children With Posterior Fossa Tumor Completed NCT04528316
49 Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, Central Nervous System (CNS)- Primitive Neuroectodermal Tumour (PNET), or Ependymoma Completed NCT02238899
50 Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma Completed NCT02747576

Search NIH Clinical Center for Childhood Medulloblastoma

Sources

Genetic Tests for Childhood Medulloblastoma

About this section
Sources

Anatomical Context for Childhood Medulloblastoma

About this section

Organs/tissues related to Childhood Medulloblastoma:

MalaCards : Brain, Nk Cells, Spinal Cord, T Cells, Endothelial, Thyroid, Bone
Sources

Publications for Childhood Medulloblastoma

About this section

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 492)
# Title Authors PMID Year
1
Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. 53 62
20053783 2010
2
RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. 53 62
19134217 2009
3
Molecular studies in pediatric medulloblastomas. 53 62
12455884 2002
4
O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. 53 62
11297257 2001
5
Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. 53 62
9731505 1998
6
Expression of the c-Myc protein in childhood medulloblastoma. 53 62
9482408 1998
7
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. 53 62
9242460 1997
8
Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. 62
36473869 2022
9
The role of apparent diffusion coefficient histogram metrics for differentiating pediatric medulloblastoma histological variants and molecular groups. 62
35798974 2022
10
MRI Radiomics Signature of Pediatric Medulloblastoma Improves Risk Stratification Beyond Clinical and Conventional MR Imaging Features. 62
36412264 2022
11
Plasma metabolite profiles identify pediatric medulloblastoma and other brain cancer. 62
36369592 2022
12
High dose craniospinal irradiation as independent risk factor of permanent alopecia in childhood medulloblastoma survivors: cohort study and literature review. 62
36369416 2022
13
Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy. 62
36334265 2022
14
Hypercarbia in a Pediatric Patient With Relapsed Medulloblastoma. 62
36348886 2022
15
Parent ratings of executive functioning in pediatric survivors of medulloblastoma and pilocytic astrocytoma. 62
36111630 2022
16
Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development. 62
35831448 2022
17
MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study. 62
35438562 2022
18
Novel neoplasms associated with syndromic pediatric medulloblastoma: integrated pathway delineation for personalized therapy. 62
35978432 2022
19
Chromosomal Instability Characterizes Pediatric Medulloblastoma but Is Not Tolerated in the Developing Cerebellum. 62
36077248 2022
20
Bone mineral density and nutrition in long-term survivors of childhood brain tumors. 62
35871919 2022
21
Nonenzymatic Multiamplified Electrochemical Detection of Medulloblastoma-Relevant MicroRNAs from Cerebrospinal Fluid. 62
35925869 2022
22
Radiogenomics for Pediatric Medulloblastoma to Predict Tumor Subtypes and Guide Therapy. 62
35438567 2022
23
Epigenetic age acceleration among survivors of pediatric medulloblastoma and primitive neuroectodermal tumor. 62
35862575 2022
24
Meta-Analysis of Apparent Diffusion Coefficient in Pediatric Medulloblastoma, Ependymoma, and Pilocytic Astrocytoma. 62
34842328 2022
25
Taste and smell function in long-term survivors after childhood medulloblastoma/CNS-PNET. 62
35426047 2022
26
GABAA receptor agonist suppresses pediatric medulloblastoma progression by inhibiting PKA-Gli1 signaling axis. 62
35331907 2022
27
Pediatric medulloblastoma express immune checkpoint B7-H3. 62
34988920 2022
28
Radiomics signature for the prediction of progression-free survival and radiotherapeutic benefits in pediatric medulloblastoma. 62
35394210 2022
29
Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma. 62
35083822 2022
30
Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. 62
34788463 2022
31
Toxicity and Clinical Results after Proton Therapy for Pediatric Medulloblastoma: A Multi-Centric Retrospective Study. 62
35681727 2022
32
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma. 62
35565414 2022
33
Neuropsychological functioning in survivors of childhood medulloblastoma/CNS-PNET: The role of secondary medical complications. 62
32729777 2022
34
Di-genic inheritance of germline POLE and PMS2 pathogenic variants causes a unique condition associated with pediatric cancer predisposition. 62
34967012 2022
35
Integration of immunohistochemistry, RNA sequencing, and multiplex ligation-dependent probe amplification for molecular classification of pediatric medulloblastoma. 62
35119194 2022
36
MTHFR single nucleotide polymorphism associated with working memory in pediatric medulloblastoma survivors. 62
34448443 2022
37
Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. 62
35190934 2022
38
Gene-Specific DNA Methylation Profiles in Pediatric Medulloblastomas. 62
34554028 2022
39
Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification. 62
35191235 2022
40
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. 62
34077540 2022
41
AI-Based Pipeline for Classifying Pediatric Medulloblastoma Using Histopathological and Textural Images. 62
35207519 2022
42
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial. 62
35719637 2022
43
MRI Correlates of Ototoxicity in the Auditory Pathway in Children Treated for Medulloblastoma. 62
34739428 2022
44
Corrigendum: Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis. 62
36452454 2022
45
Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma. 62
35053583 2022
46
Childhood Medulloblastoma: An Overview. 62
34978683 2022
47
Chromatin Immunoprecipitation Assays on Medulloblastoma Cell Line DAOY. 62
34978686 2022
48
Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis. 62
36133906 2022
49
High expression of Toll-like receptor 7 is a survival factor in pediatric medulloblastoma. 62
34480601 2021
50
A CBF decrease in the left supplementary motor areas: New insight into postoperative pediatric cerebellar mutism syndrome using arterial spin labeling perfusion MRI. 62
34259072 2021
Sources

Variations for Childhood Medulloblastoma

About this section
Sources

Expression for Childhood Medulloblastoma

About this section
Search GEO for disease gene expression data for Childhood Medulloblastoma.
Sources

Pathways for Childhood Medulloblastoma

About this section

Pathways related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.81 TP53 SUFU PTCH1 NRG1 MYC GLI1
2
Disease 66
Show member pathways
 13.8 TP53 SHH NRG1 MYC H2AC18 ERBB4
3
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.55 SUFU PTCH1 NRG1 GLI1 ERBB4 ERBB3
4
Prolactin Signaling 64
Show member pathways
 13.46 TP53 NRG1 MYC MGMT ERBB4 ERBB3
5
RAF/MAP kinase cascade 66
Show member pathways
 13.37 SHH NRG1 MYC ERBB4 ERBB3 ERBB2
6
PIP3 activates AKT signaling 66
Show member pathways
 13.06 EGFR ERBB2 ERBB3 ERBB4 NRG1 TP53
7
Signal Transduction 66
12.94 TP53 TERT SUFU SHH PTCH1 NRG1
8
Signaling by Receptor Tyrosine Kinases 66
12.83 NRG1 MYCN MYC ERBB4 ERBB3 ERBB2
9
Endometrial cancer 74
Show member pathways
 12.7 TP53 MYC ERBB4 ERBB2 EGFR
10
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 66
Show member pathways
 12.68 NRG1 ERBB4 ERBB3 ERBB2 EGFR
11
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.62 TP53 TERT NRG1 MYC EGFR
12
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.45 TP53 NRG1 ERBB3 ERBB2
13
Breast cancer pathway 74
Show member pathways
 12.45 TP53 MYC ERBB2 EGFR
14
Signaling by Hedgehog 66
Show member pathways
 12.45 SUFU SHH PTCH1 GLI2 GLI1
15
NF-kappaB Pathway 70
Show member pathways
 12.44 EGFR ERBB2 ERBB3 ERBB4 TP53
16
Development EGFR signaling pathway 22
Show member pathways
 12.4 TP53 NRG1 MYC ERBB4 ERBB3 ERBB2
17
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.38 NRG1 ERBB4 ERBB3 ERBB2 EGFR
18
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.32 NRG1 ERBB3 ERBB2 EGFR
19
Wnt / Hedgehog / Notch 3
12.27 SUFU SHH PTCH1 GLI2 GLI1
20
Signaling by ERBB2 KD Mutants 66
Show member pathways
 12.26 NRG1 ERBB4 ERBB3 ERBB2 EGFR
21
MAPK Signaling: Mitogens 65
Show member pathways
 12.2 TP53 MYC ERBB4 ERBB3 ERBB2 EGFR
22
Signaling by PTK6 66
Show member pathways
 12.17 NRG1 ERBB4 ERBB3 ERBB2 EGFR
23
Tyrosine Kinases / Adaptors 3
12.14 EGFR ERBB2 ERBB3 ERBB4 NRG1
24
mTOR Signaling 65
12.1 TP53 ERBB4 ERBB3 ERBB2 EGFR
25
Signaling by ERBB4 66
Show member pathways
 12.07 NRG1 ERBB4 ERBB3 ERBB2 EGFR
26
Signaling by ERBB2 66
Show member pathways
 11.99 NRG1 ERBB4 ERBB3 ERBB2 EGFR
27
MAPK Pathway 70
Show member pathways
 11.96 TP53 ERBB4 ERBB3 ERBB2 EGFR
28
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 66
Show member pathways
 11.84 MYC ERBB2 EGFR
29
Validated targets of C-MYC transcriptional activation 61
11.79 TP53 TERT MYC
30
Head and neck squamous cell carcinoma 74
11.78 TP53 TERT ERBB2 EGFR
31
G-protein signaling_RhoA regulation pathway 22
11.75 EGFR ERBB2 ERBB3 ERBB4 NRG1
32
Physico-chemical features and toxicity-associated pathways 74
11.71 MYC ERBB4 ERBB2 EGFR
33
Regulation of Telomerase 61
11.7 TERT MYC EGFR
34
Pathways affected in adenoid cystic carcinoma 74
11.66 TP53 MYCN ERBB2
35
Neurogenesis regulation in the olfactory epithelium 74
11.61 NRG1 MYC ERBB4
36
Agrin Interactions at Neuromuscular Junction 64
11.56 NRG1 ERBB4 ERBB3 ERBB2 EGFR
37
Alzheimers Disease Pathway 64
11.48 EGFR ERBB2 ERBB3 ERBB4
38
Development of ureteric collection system 74
11.46 GLI1 GLI2 MYCN SHH
39
a6b1 and a6b4 Integrin signaling 61
11.41 ERBB3 ERBB2 EGFR
40
Signaling events mediated by the Hedgehog family 61
Show member pathways
 11.39 SHH PTCH1 GLI2
41
Tumor suppressor activity of SMARCB1 74
Show member pathways
 11.36 PTCH1 GLI2 GLI1
42
Bladder cancer 74
11.36 TP53 MYC ERBB2 EGFR
43
Hedgehog signaling pathway 74
11.34 GLI1 GLI2 PTCH1 SHH SUFU
44
ErbB2/ErbB3 signaling events 61
11.33 NRG1 ERBB3 ERBB2
45
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.32 SHH PTCH1 GLI2 GLI1
46
Gastric cancer network 2 74
11.31 TP53 MYC EGFR
47
Dopaminergic neurogenesis 74
11.3 SHH GLI2 GLI1
48
Hedgehog signaling events mediated by Gli proteins 61
11.23 SUFU SHH PTCH1 GLI2 GLI1
49
Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) 74
11.06 MYC ERBB4 ERBB3 ERBB2 EGFR
50
Mammary gland development pathway - Embryonic development (Stage 1 of 4) 74
11.05 TERT MYC ERBB4
Sources

GO Terms for Childhood Medulloblastoma

About this section

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary tip GO:0097542 9.88 SUFU GLI2 GLI1
2 basal plasma membrane GO:0009925 9.86 ERBB4 ERBB3 ERBB2 EGFR
3 ciliary base GO:0097546 9.85 SUFU GLI2 GLI1
4 ERBB3:ERBB2 complex GO:0038143 9.62 ERBB3 ERBB2
5 GLI-SUFU complex GO:1990788 9.55 SUFU GLI2 GLI1
6 plasma membrane region GO:0098590 9.26 ERBB4 ERBB3 ERBB2 EGFR
7 obsolete spanning component of plasma membrane GO:0044214 8.92 ERBB4 ERBB3 ERBB2 EGFR

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.5 EGFR ERBB4 GLI1 GLI2 MYC MYCN
2 positive regulation of gene expression GO:0010628 10.42 ERBB2 ERBB3 MYC MYCN NRG1 SHH
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.3 ERBB4 ERBB3 ERBB2 EGFR
4 peptidyl-tyrosine phosphorylation GO:0018108 10.26 ERBB4 ERBB3 ERBB2 EGFR
5 positive regulation of kinase activity GO:0033674 10.25 ERBB4 ERBB3 ERBB2 EGFR
6 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 10.19 TERT EGFR CUL4A
7 branching involved in ureteric bud morphogenesis GO:0001658 10.18 SHH PTCH1 MYC
8 cellular response to epidermal growth factor stimulus GO:0071364 10.18 EGFR ERBB2 ERBB4
9 positive regulation of protein tyrosine kinase activity GO:0061098 10.17 EGFR ERBB3 ERBB4 NRG1
10 smoothened signaling pathway GO:0007224 10.16 SUFU SHH PTCH1 GLI2 GLI1
11 positive regulation of DNA replication GO:0045740 10.14 GLI2 GLI1 EGFR
12 stem cell proliferation GO:0072089 10.14 TP53 SHH PTCH1 GLI2
13 positive regulation of miRNA transcription GO:1902895 10.12 TP53 TERT MYC EGFR
14 pattern specification process GO:0007389 10.11 SHH PTCH1 GLI2
15 dorsal/ventral pattern formation GO:0009953 10.1 SHH PTCH1 GLI2 GLI1
16 positive regulation of epithelial cell proliferation GO:0050679 10.1 SHH MYC GLI2 ERBB2 EGFR
17 heart development GO:0007507 10.1 TP53 SHH NRG1 GLI2 ERBB4 ERBB3
18 oligodendrocyte differentiation GO:0048709 10.09 SHH NRG1 ERBB2
19 embryonic organ development GO:0048568 10.09 TP53 SHH PTCH1
20 mammary gland epithelial cell differentiation GO:0060644 10.09 PTCH1 MGMT ERBB4
21 prostate gland development GO:0030850 10.08 GLI1 PTCH1 SHH
22 cell population proliferation GO:0008283 10.08 TP53 SHH NRG1 GLI2 EGFR CUL4A
23 peripheral nervous system development GO:0007422 10.07 NRG1 ERBB3 ERBB2
24 mammary gland development GO:0030879 10.06 PTCH1 NRG1 GLI2
25 negative regulation of smoothened signaling pathway GO:0045879 10.06 GLI2 PTCH1 SUFU
26 positive regulation of cardiac muscle cell proliferation GO:0060045 10.05 ERBB4 GLI1 NRG1
27 spinal cord motor neuron differentiation GO:0021522 10.03 SHH PTCH1 GLI2
28 epithelial cell proliferation GO:0050673 10.02 SHH PTCH1 GLI2 EGFR
29 ERBB4-ERBB4 signaling pathway GO:0038138 10.01 ERBB4 NRG1
30 negative regulation of protein catabolic process GO:0042177 10.01 SHH NRG1 EGFR
31 digestive tract morphogenesis GO:0048546 10 SHH GLI1 EGFR
32 positive regulation of striated muscle cell differentiation GO:0051155 9.99 SHH NRG1
33 cerebellar cortex morphogenesis GO:0021696 9.99 GLI1 GLI2
34 hindgut morphogenesis GO:0007442 9.98 SHH GLI2
35 ERBB4 signaling pathway GO:0038130 9.98 NRG1 ERBB4
36 dorsal/ventral neural tube patterning GO:0021904 9.98 SHH PTCH1 GLI2
37 smoothened signaling pathway involved in ventral spinal cord interneuron specification GO:0021775 9.97 GLI2 SUFU
38 negative regulation of secretion GO:0051048 9.97 ERBB3 NRG1
39 ERBB2-ERBB4 signaling pathway GO:0038135 9.95 ERBB2 ERBB4 NRG1
40 multicellular organism development GO:0007275 9.94 ERBB4 ERBB3 ERBB2 EGFR
41 neurogenesis GO:0022008 9.92 EGFR ERBB2 ERBB3 ERBB4
42 mammary gland duct morphogenesis GO:0060603 9.88 GLI2 PTCH1
43 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.87 SUFU GLI2
44 negative regulation of hh target transcription factor activity GO:1990787 9.85 SUFU GLI2 GLI1
45 ERBB2-ERBB3 signaling pathway GO:0038133 9.85 ERBB2 ERBB3 NRG1
46 smoothened signaling pathway involved in spinal cord motor neuron cell fate specification GO:0021776 9.83 SUFU GLI2
47 positive regulation of miRNA maturation GO:1903800 9.83 TP53 MYCN EGFR
48 spinal cord dorsal/ventral patterning GO:0021513 9.83 GLI2 SHH SUFU
49 negative regulation of apoptotic process GO:0043066 9.83 TP53 TERT SHH MYC MGMT GLI2
50 regulation of cell population proliferation GO:0042127 9.81 EGFR ERBB2 ERBB3 ERBB4 PTCH1 SHH

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.97 ERBB4 ERBB3 ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.7 ERBB4 ERBB3 ERBB2 EGFR
3 neuregulin receptor activity GO:0038131 9.62 ERBB4 ERBB3
4 epidermal growth factor receptor activity GO:0005006 9.56 ERBB4 EGFR
5 ErbB-3 class receptor binding GO:0043125 9.43 NRG1 ERBB3 ERBB2
6 protein tyrosine kinase activator activity GO:0030296 9.23 NRG1 ERBB4 ERBB3 EGFR
Sources

Sources for Childhood Medulloblastoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....